obesity research comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
== History == From 1946 to 1948, the eleven states formed a single British crown colony known as the Malayan Union. Due to opposition from Malay nationalists, the Union was disbanded and replaced by the Federation of Malaya, which restored the symbolic positions of the rulers of the Malay states and introduced greater restrictions on the attainment of citizenship status. Within the Federation, while the Malay states were protectorates of the United Kingdom, Penang and Malacca remained British colonial territories. Like the Malayan Union before it, the Federation did not include Singapore, despite its traditional connections with Malaya. The Malaya Agreement was formulated by the British–Malay Pleno Conference between June and December 1946. At the end of the meeting, the Pleno Conference produced a 100-page "Blue Book." It was signed on 21 January 1948 at King House by the Malay rulers, and by Sir Edward Gent as the representative of the British government. The Agreement superseded the Agreement creating the Malayan Union, and prepared for the establishment of the Federation of Malaya on 1 February 1948. The position of the Malay rulers was also restored. The Federation became independent from British colonial rule and became an independent member of the Commonwealth of Nations on 31 August 1957. In 1963, the Federation was reconstituted as "Malaysia" when it federated with the British territories of Singapore, Sarawak, and North Borneo; a claim to the latter territory was maintained by the Philippines.
GSK-3 functions by phosphorylating a serine or threonine residue on its target substrate. A positively charged pocket adjacent to the active site binds a "priming" phosphate group attached to a serine or threonine four residues C-terminal of the target phosphorylation site. The active site, at residues 181, 200, 97, and 85, binds the terminal phosphate of ATP and transfers it to the target location on the substrate (see figure 1).
Britain was irritated by several French actions following the Treaty of Amiens. Bonaparte annexed Piedmont and Elba, made himself President of the Italian Republic, a state in northern Italy that France had set up, and failed to evacuate Holland, as it had agreed to do in the treaty. France then continued to interfere with British trade despite peace having been made and complained about Britain harbouring certain individuals and not cracking down on the anti-French press. Malta was captured by Britain during the war and was subject to a complex arrangement in the 10th article of the Treaty of Amiens, where it was to be restored to the Knights of St. John with a Neapolitan garrison and placed under the guarantee of third powers. The weakening of the Knights of St. John by the confiscation of their assets in France and Spain along with delays in obtaining guarantees prevented the British from evacuating it after three months as stipulated in the treaty.
Agonists Cortagine Corticorelin Corticotropin-releasing hormone Sauvagine Stressin I Urocortin Antagonists Antalarmin Astressin-B CP-154,526 Emicerfont Hypericin LWH-234 NBI-27914 NBI-74788 Pexacerfont R-121919 TS-041 Verucerfont
Sources: en.wikipedia.org
As with any sterilisation method, a very small proportion of germs may survive the process, and cause a fraction of the irradiated products to spoil anyway. The risk comes from the false sense of security. As mentioned above, the treatment only preserves the freshness of the product at the moment it reaches the factory. If it has already lost some of its qualities, this will not be restored, and may even be hidden by the packaging. While the purpose of the irradiation is to degrade the DNA/RNA of contaminating germs, a small proportion of the nutrient load is also degraded in the process. In particular, vitamins, whole proteins and aromatic molecules. The irradiation creates highly reactive radicals, which would cause problems if the food is consumed immediately after being irradiated.
The water activity, aw, in a fish is defined as the ratio of the water vapour pressure in the flesh of the fish to the vapour pressure of pure water at the same temperature and pressure. It ranges between 0 and 1, and is a parameter that measures how available the water is in the flesh of the fish. Available water is necessary for the microbial and enzymatic reactions involved in spoilage. There are a number of techniques that have been or are used to tie up the available water or remove it by reducing the aw. Traditionally, techniques such as drying, salting and smoking have been used, and have been used for thousands of years. These techniques can be very simple, for example, by using solar drying. In more recent times, freeze-drying, water-binding humectants, and fully automated equipment with temperature and humidity control have been added. Often a combination of these techniques is used.
==== MeSH D08.811.150 – dna restriction-modification enzymes ==== MeSH D08.811.150.240 – dna modification methylases MeSH D08.811.150.280 – dna restriction enzymes MeSH D08.811.150.280.250 – deoxyribonucleases, type i site-specific MeSH D08.811.150.280.260 – deoxyribonucleases, type ii site-specific MeSH D08.811.150.280.260.240 – deoxyribonuclease bamhi MeSH D08.811.150.280.260.300 – deoxyribonuclease ecori MeSH D08.811.150.280.260.400 – deoxyribonuclease hindiii MeSH D08.811.150.280.260.420 – deoxyribonuclease hpaii MeSH D08.811.150.280.270 – deoxyribonucleases, type iii site-specific
== Research areas == RCB engages in contemporary research at the interface of disciplines constituting biotechnology in its broadest definition. Research programmes aim to integrate science, engineering, medicine and agriculture in biotechnology and emphasize on their relevance to the regional societies. A broad range of research areas planned include:
Polyvinylidene fluoride or polyvinylidene difluoride (PVDF) is a highly non-reactive thermoplastic fluoropolymer produced by the polymerization of vinylidene difluoride. Its chemical formula is (C2H2F2)n. PVDF is a specialty plastic used in applications requiring the highest purity, as well as resistance to solvents, acids and hydrocarbons. PVDF has a lower density of 1.78 g/cm3 in comparison to other fluoropolymers, like polytetrafluoroethylene. It is available in the form of piping products, sheet, tubing, films, plate and an insulator for premium wire. It can be injected, molded or welded and is commonly used in the chemical, semiconductor, medical and defense industries, as well as in lithium-ion batteries. It is also available as a cross-linked closed-cell foam, used increasingly in aviation and aerospace applications, and as an exotic 3D printer filament. It can also be used in repeated contact with food products, as it is FDA-compliant and non-toxic below its degradation temperature. As a fine powder grade, it is an ingredient in high-end paints for metals. These PVDF paints have extremely good gloss and color retention. They are in use on many prominent buildings around the world, such as the Petronas Towers in Malaysia and Taipei 101 in Taiwan, as well as on commercial and residential metal roofing. In biotechnology, PVDF membranes are used to immobilize proteins for a western blot. PVDF is also used as a binder component for the carbon electrode in supercapacitors and for other electrochemical applications.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.